PCXYLOB Stock Latest News
Private CompaniesXylo Bio Features UW-Madison Psychedelic Research Discussion3d agoXYLOB
Private CompaniesXylo Bio Donates $2,650 to Mental Health Research6d agoXYLOB
Private CompaniesXylo Bio Highlights Challenges in Psychiatric Biomarker Development1w agoXYLOB
Private CompaniesXylo Bio Highlights Conference Participation and Neuroscience Outreach2w agoXYLOB
Private CompaniesXylo Bio Targets Student Talent to Support Drug Discovery Operations3w agoXYLOB
Private CompaniesXylo Bio Selected for NIH HEAL Preclinical Pain Screening Program1M agoXYLOBPrivate CompaniesXylo Bio Emphasizes Biomarker-Driven Approach to Depression Drug Development1M agoXYLOB
Private CompaniesXylo Bio Emphasizes Inclusive Clinical Development in Neuroscience Pipeline1M agoXYLOB
Private CompaniesXylo Bio Highlights Mental Health Engagement Through Community Hike Initiative1M agoXYLOB
Private CompaniesXylo Bio Progresses Neuropsychiatric Candidate XYL-1001 Into Phase 1 Trials1M agoXYLOB
Private CompaniesXylo Bio Advances XYL-1001 Into First-in-Human Phase 1 Trial1M agoXYLOB
Private CompaniesXylo Bio Advances Lead Neurotherapeutic Candidate Into Phase 1 Clinical Trials2M agoXYLOB
Private CompaniesXylo Bio Showcases Expertise in Rapid-Acting Antidepressant Mechanisms2M agoXYLOB
Private CompaniesAccelerator Participation Underscores Xylo Bio’s Neurotech Focus2M agoXYLOB
Private CompaniesXylo Bio Emphasizes Rigorous Study Design in Neurotherapeutics Pipeline2M agoXYLOB
Private CompaniesXylo Bio CSO to Present Neurotherapeutics Research at Industry Conference2M agoXYLOB
Private CompaniesConference Engagement Highlights Xylo Bio’s Focus on Neuropsychiatric Drug Development2M agoXYLOBPrivate CompaniesXylo Bio Highlights Clinical Trial Focus on Deep Brain Stimulation for Chronic Pain3M agoXYLOB



